Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Rating of “Moderate Buy” from Analysts

Immuneering Corporation (NASDAQ:IMRX) has been assigned an average rating of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $16.50.

Several equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research report on Monday, December 29th. Wall Street Zen cut shares of Immuneering from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Needham & Company LLC increased their price target on shares of Immuneering from $8.00 to $11.00 and gave the company a “buy” rating in a report on Monday, September 15th. Mizuho set a $12.00 price target on shares of Immuneering in a research report on Wednesday, October 29th. Finally, Chardan Capital restated a “buy” rating and set a $20.00 price objective on shares of Immuneering in a report on Thursday, November 13th.

Institutional Investors Weigh In On Immuneering

Institutional investors have recently bought and sold shares of the business. Sanofi acquired a new position in shares of Immuneering in the 3rd quarter valued at $18,960,000. Vanguard Group Inc. lifted its stake in Immuneering by 128.5% during the third quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock worth $16,907,000 after purchasing an additional 1,358,322 shares during the period. Citadel Advisors LLC bought a new position in Immuneering during the third quarter worth about $6,602,000. Blue Owl Capital Holdings LP acquired a new stake in Immuneering during the third quarter valued at approximately $3,850,000. Finally, Monashee Investment Management LLC bought a new stake in shares of Immuneering in the 3rd quarter valued at approximately $2,100,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

Immuneering Stock Up 1.7%

Shares of Immuneering stock opened at $6.72 on Wednesday. Immuneering has a 12-month low of $1.10 and a 12-month high of $10.08. The stock has a 50 day moving average price of $6.62 and a two-hundred day moving average price of $5.72. The stock has a market capitalization of $433.91 million, a P/E ratio of -3.78 and a beta of 0.48.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). Sell-side analysts anticipate that Immuneering will post -1.86 earnings per share for the current year.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.